Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study.
Lück HJ, Schmidt M, Hesse T, Hoffmann O, Heinrich BJ, Park-Simon TW, Grischke EM, Weide R, Müller-Huesmann H, Lüdtke-Heckenkamp K, Fischer D, Zemlin C, Kögel M, Wu J, Schmitz H, Engelbrecht C, Jackisch C. Lück HJ, et al. Oncologist. 2023 Dec 11;28(12):e1152-e1159. doi: 10.1093/oncolo/oyad191. Oncologist. 2023. PMID: 37555463 Free PMC article.
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S. von Minckwitz G, et al. Among authors: luck hj. J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980081 Clinical Trial.
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R. Harbeck N, et al. Among authors: luck hj. Breast Care (Basel). 2013 May;8(2):110-20. doi: 10.1159/000350777. Breast Care (Basel). 2013. PMID: 24419247 Free PMC article.
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.
Harbeck N, Marschner N, Untch M, Decker T, Hegewisch-Becker S, Jackisch C, Huober J, Lück HJ, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Wuerstlein R, Thomssen C. Harbeck N, et al. Among authors: luck hj. Breast Care (Basel). 2014 Feb;9(1):52-9. doi: 10.1159/000358689. Breast Care (Basel). 2014. PMID: 24803888 Free PMC article.
Optimal Sequencing of Anti-HER2 Therapy.
Lück HJ, Untch M, Jackisch C, Zielinski C, Bartsch R. Lück HJ, et al. Breast Care (Basel). 2014 May;9(2):138-40. doi: 10.1159/000362300. Breast Care (Basel). 2014. PMID: 24944559 Free PMC article. No abstract available.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S. Lück HJ, et al. Breast Cancer Res Treat. 2015 Jan;149(1):141-9. doi: 10.1007/s10549-014-3217-y. Epub 2014 Dec 18. Breast Cancer Res Treat. 2015. PMID: 25519041 Clinical Trial.
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F. Emons G, et al. Among authors: luck hj. Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28. Gynecol Oncol. 2016. PMID: 26731724 Clinical Trial.
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D, Hilpert F, González Martin A, Rau J, Ottevanger P, Greimel E, Lück HJ, Selle F, Colombo N, Kroep JR, Mirza MR, Berger R, Pardo B, Grischke EM, Berton-Rigaud D, Martinez-Garcia J, Vergote I, Redondo A, Cardona A, Bastière-Truchot L, du Bois A, Kurzeder C; PENELOPE trial investigators. Lorusso D, et al. Among authors: luck hj. Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147. doi: 10.1136/ijgc-2019-000370. Epub 2019 Aug 15. Int J Gynecol Cancer. 2019. PMID: 31420414 Clinical Trial.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
124 results